Transition From COVID-19 Emergency: Demystify the FDA Requirements to Keep Your Device on The Market

On March 27, 2023, the FDA released its guidance Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to COVID-19. In this webinar, Dr. Jianlin Song of Wilson Elser Moskowitz Edelman & Dicker LLP and Dr. Christie Bergerson of Exponent review the latest guidance and discuss which groups of medical devices are impacted and the legal ramifications.

This webinar will cover:

- What are the main groups of medical devices impacted?
- High level: How to go from EUA to traditional submission (EUA guidance doc).
- High level: Phased approach to traditional submission – non-EUA (Phased guidance doc).
- Legal ramifications: Overview and Prospective.

Dr. Christie Bergerson | Manager | Exponent



Dr. Jianlin Song | Partner | Wilson Elser

Dr. Song, MD, JD, is a Partner in the Life Science Litigation Group at Wilson Elser Moskowitz Edelman and Dicker LLP’s San Francisco office. During her 15 years of legal practice, Dr. Song has defended manufacturers of a broad spectrum of life science products, from food supplements and dental adhesives to prescription drugs and Class II medical devices such as joint replacements, electroconvulsive therapy devices and cold therapy devices. She has also defended diagnostic laboratories, fertility centers, and various medical, dental and psychiatric professionals in malpractice cases. Among her many successes, Dr. Song won a motion for summary judgment for the manufacturer of a 3D-printed joint prosthesis in what was likely the first products liability case against a 3D device in California. In addition to litigation, Dr. Song counsels small businesses, both domestic and international, on pre- and post-marketing compliance issues. She has helped companies from various parts of Asia bring hand sanitizers and other PPEs onto the United States market during the COVID-19 pandemic.